Market Cap | 543.65M | P/E | - | EPS this Y | 31.70% | Ern Qtrly Grth | - |
Income | -233.98M | Forward P/E | -3.73 | EPS next Y | 17.10% | 50D Avg Chg | 12.00% |
Sales | 10.5M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 36.00% |
Dividend | N/A | Price/Book | 2.03 | EPS next 5Y | - | 52W High Chg | -17.00% |
Recommedations | 1.80 | Quick Ratio | 18.19 | Shares Outstanding | 266.09M | 52W Low Chg | 96.00% |
Insider Own | 18.03% | ROA | -18.50% | Shares Float | 131.75M | Beta | 2.04 |
Inst Own | 75.97% | ROE | -61.80% | Shares Shorted/Prior | 10.73M/12.42M | Price | 3.13 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 730,825 | Target Price | 10.40 |
Oper. Margin | -1,839.25% | Earnings Date | Aug 8 | Volume | 386,508 | Change | -0.63% |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
Needham | Buy | Jun 17, 24 |
Needham | Buy | Jun 3, 24 |
Needham | Buy | May 17, 24 |
Needham | Buy | Apr 12, 24 |
Truist Securities | Buy | Apr 9, 24 |
Truist Securities | Buy | Mar 18, 24 |
Needham | Buy | Mar 14, 24 |
Needham | Buy | Feb 12, 24 |
Needham | Buy | Jan 22, 24 |